The Innovative Genomics Institute (IGI) is at the forefront of utilizing genome engineering technologies, particularly CRISPR, to address significant global challenges in health, climate, and sustainable agriculture. Founded by Nobel Laureate Jennifer Doudna, the institute focuses on various research programs, including human health initiatives like the Sickle Cell Initiative and microbiome editing, as well as climate-related projects such as CRISPR applications for climate change and plant genomics. The IGI is also dedicated to enhancing the accessibility and affordability of CRISPR technologies, ensuring that advancements in genome editing can benefit diverse populations, including farmers and patients with genetic disorders.

In the realm of clinical applications, IGI has been instrumental in the development of CRISPR-based therapies, marking significant milestones such as the approval of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. This therapy exemplifies the potential of CRISPR to provide curative solutions for genetic disorders. Additionally, IGI is exploring innovative approaches to improve CRISPR treatments, including in vivo editing and targeted delivery methods, which could enhance patient outcomes and broaden the accessibility of these groundbreaking therapies. The institute's commitment to advancing CRISPR technology is further exemplified through collaborations, such as the Center for CRISPR Target Discovery, aimed at accelerating the identification and validation of new therapeutic targets for various diseases.

United States

Founded by Jennifer Doudna, the Innovative Genomics Institute advances genome engineering to cure disease and ensure food security.

Innovative Genomics Institute

Company Details